2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

blast cells

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

2

Peptides

8

Inhibitory Antibodies

3

Natural
Products

1

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1923
    L-Asparaginase
    Maximum Cited Publications
    15 Publications Verification

    L-​ASNase

    		 Apoptosis DNA/RNA Synthesis Cancer
    L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis .
    L-Asparaginase
  • HY-P99234
    Pivekimab

    		Interleukin Related ADC Antibody Cancer
    Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
    Pivekimab
  • HY-P99971
    Gemtuzumab

    		ADC Antibody Transmembrane Glycoprotein Cancer
    Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Gemtuzumab
  • HY-18948
    GSK321
    1 Publications Verification

    		 Isocitrate Dehydrogenase (IDH) Cancer
    GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
    GSK321
  • HY-15611
    KPT-185

    		CRM1 Cancer
    KPT-185 is an orally bioavailable and selective inhibitor of CRM1 and displays potent antiproliferative properties at submicromolar concentrations (IC50=100-500 nM), induces apoptosis, cell-cycle arrest, and myeloid differentiation in AML cell lines and patient blasts .
    KPT-185
  • HY-119323
    7-Azido-4-methylcoumarin
    1 Publications Verification

    		 Fluorescent Dye Others
    7-Azido-4-methylcoumarin is a selective coumarin-based fluorescent probe for hydrogen sulfide (H2S). In the presence of H2S, the aromatic azido group of 7-Azido-4-methylcoumarin is selectively reduced to produce the fluorescently active 7-amino-4-methylcoumarin (AMC). 7-Azido-4-methylcoumarin binds to the coumarin/phenol-binding site of BSA, the aglycone-binding site of UGT1A6, and the substrate-binding site of SULT1A1, respectively. 7-Azido-4-methylcoumarin retains its fluorescent properties after covalent binding, acts as a fluorescent H2S probe, and does not react with cysteine, homocysteine or glutathione (Ex/Em = 340/445 nm) .
    7-Azido-4-methylcoumarin
  • HY-N6784
    Oligomycin B

    		ATP Synthase Bacterial Apoptosis Antibiotic Infection Neurological Disease
    Oligomycin B is an antibiotic that acts as a non-selective inhibitor of ATP Synthase. Oligomycin B increases mitochondrial membrane potential. Oligomycin B induces apoptosis and necrosis. Oligomycin B impairs the motility of Plasmopara viticola zoospores and induces their lysis. Oligomycin B inhibits Magnaporthe oryzae (wheat blast fungus) and suppresses the development of wheat blast. Oligomycin B reduces hyphal growth and spore germination of Botrytis cinerea, and protects Arabidopsis thaliana against Botrytis cinerea infection. Oligomycin B exacerbates cytotoxic brain edema in rats with cerebral cortical contusion, increases intracranial pressure and brain water content, and aggravates mitochondrial damage in these rats. Oligomycin B is used in studies related to grape downy mildew, traumatic brain injury, wheat blast, and gray mold .
    Oligomycin B
  • HY-171792
    BMS-986497

    ORM-6151

    		 Transmembrane Glycoprotein Cancer
    BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML) .
    BMS-986497
  • HY-16271
    Kevetrin hydrochloride
    4 Publications Verification

    4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride

    		 MDM-2/p53 Apoptosis Cancer
    Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .
    Kevetrin hydrochloride
  • HY-108894
    Ferumoxytol

    		Ferroptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Cancer
    Ferumoxytol is an FDA-approved ultrasmall superparamagnetic iron oxide preparation and iron replacement agent that exerts selective activity against leukemia cells with low ferroportin expression. Ferumoxytol increases intracellular iron levels, induces reactive oxygen species (ROS) production via the Fenton reaction, and triggers oxidative stress and cell death. Ferumoxytol reduces disease burden in mouse models and patient-derived leukemia models. As an MRI contrast agent, Ferumoxytol enables imaging of vascular lesions, tumors and lymph nodes. Ferumoxytol can be used in research related to acute myeloid leukemia and blast-phase chronic myeloid leukemia .
    Ferumoxytol
  • HY-B0848
    Tricyclazole
    2 Publications Verification

    		 Environmental Pollutants Bacterial Infection Metabolic Disease
    Tricyclazole is a pentaketone melanin biosynthesis inhibitor and a unique fungicide for controlling rice blast. Tricyclazole alters the structure and function of fungal cell walls, reduces fungal pathogenicity and penetration, and causes dose-dependent liver damage in animals .
    Tricyclazole
  • HY-128888B
    (S,R)-GSK321

    		Isocitrate Dehydrogenase (IDH) Cancer
    (S,R)-GSK321 is the (S,R)-enantiomer of GSK321 (HY-18948). GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
    (S,R)-GSK321
  • HY-160952
    Cytarabine-daunorubicin

    CPX 351; Daunorubicin-Cytarabine Liposome

    		 Liposome Drug Derivative Cardiovascular Disease Cancer
    Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia .
    Cytarabine-daunorubicin
  • HY-P991517
    BI-836858

    		Transmembrane Glycoprotein Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
    BI-836858
  • HY-P990905
    Bexatamig

    SAR-443579

    		 Interleukin Related Cancer
    Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .
    Bexatamig
  • HY-P11343
    Verlamelin B

    		Fungal Infection
    Verlamelin B (Compound 147) is effective against plant pathogenic fungal and is a derivative of Verlamelin (HY-N14856).Verlamelin B exhibits potent plant protective activity in vivo, particularly against rice blast and barley powdery mildew. Verlamelin B causes morphological changes in fungal cells, such as swelling or expansion. Verlamelin B exhibits weaker antifungal activity in vitro against plant pathogens such as rice blast, Dipolaris zeae, and Botrytis cinerea. Verlamelin B is useful for research on antifungal activities against plant pathogens .
    Verlamelin B
  • HY-P991294
    MGTA-117 Antibody

    		ADC Antibody Cancer
    MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
    MGTA-117 Antibody
  • HY-N17503
    Medicagenic acid 3-O-glucoside

    		Fungal Infection
    Medicagenic acid 3-O-glucoside is a monosaccharide-chain triterpenoid saponin antifungal agent that can be isolated from the roots of Medicago sativa. Against Pyricularia oryzae, Medicagenic acid 3-O-glucoside has a MIC of 0.03 mg/mL and a MFC of 0.125 mg/mL. Medicagenic acid 3-O-glucoside alters the permeability of fungal cell membranes, causing cell rupture and inhibiting fungal growth. Medicagenic acid 3-O-glucoside can be used in studies related to rice blast .
    Medicagenic acid 3-O-glucoside
  • HY-106326
    ME 2303

    FAD 104

    		 Others Cancer
    ME 2303 (FAD 104) is a fluoro-pyranosyl adriamycin analogue with anti-tumor potential. ME 2303 can inhibit the proliferation of acute undifferentiated myeloblastic leukemia (AML) blast cells in a dose-dependent manner. ME 2303 can be used for the study of acute undifferentiated myeloblastic leukemia (AML) .
    ME 2303
  • HY-W715389
    Coumoxystrobin

    		Fungal Infection
    Coumoxystrobin is a methoxyacrylate strobilurin fungicide with anti-fungal activity. Coumoxystrobin exhibits inhibitory activity against mycelial growth of Magnaporthe oryzae, increases cell membrane permeability, and reduces respiration. Coumoxystrobin shows protective activity against Magnaporthe oryzae in detached barley leaves. Coumoxystrobin reduces ATP activity of Chlorella vulgaris, thereby causing algal death. Coumoxystrobin can be used in studies related to rice blast disease .
    Coumoxystrobin
  • HY-P992389
    IO-202

    		LILRB Cancer
    IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors .
    IO-202
  • HY-123153
    GSK990

    		Isocitrate Dehydrogenase (IDH) Cancer
    GSK990 is an inactive mutant IDH1 inhibitor with no significant inhibitory activity against wild-type or mutant IDH1/IDH2 enzymes. In experiments, GSK990 can serve as an inactive negative control for the IDH1 inhibitor GSK321 (HY-18948). GSK990 is applicable to the research of acute myeloid leukemia .
    GSK990
  • HY-P992209
    Anti-CD318/CDCP1 Antibody (25A11)

    		Transmembrane Glycoprotein Cancer
    Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research .
    Anti-CD318/CDCP1 Antibody (25A11)
  • HY-122670
    VS-II-173

    		Pim Apoptosis AMPK DYRK STAT MDM-2/p53 Cancer
    VS-II-173 is a pan-Pim kinase inhibitor with IC50 values ​​of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPKα1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC50 > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations .
    VS-II-173
  • HY-124693
    DB1055

    		Apoptosis Cancer
    DB1055 is a HOXA9 inhibitor that competes with HOXA9 binding to DNA (blocking its DNA interaction activity). DB1055 induces in vitro cell growth reduction, cell apoptosis, and differentiation in human acute myeloid leukemia (AML) cells. DB1055 leads to monocyte-to-macrophage differentiation and exhibits antileukemic activities in a human THP-1 AML in vivo model. DB1055 does not impact human CD34+ bone marrow cells. DB1055 can be used for the research of acute myeloid leukemia[1].
    DB1055
  • HY-P11699
    AAPDNRETF

    		Inflammation/Immunology
    AAPDNRETF is a dominant minor histocompatibility antigen presented by H-2D b， which antigen is expressed in C57BL/6 mice and can be recognized by T cells from C3H.SW mice, thereby inducing a strong immune response. AAPDNRETF can induce graft-versus-host disease in irradiated C57BL/6 recipient mice via transfer of sensitized T lymphocytes. AAPDNRETF is applicable to the research of graft-versus-host disease .
    AAPDNRETF
  • HY-P991896
    AT1412

    AT14-012

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells [1] .
    AT1412

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: